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Abstract 
 
Introduction: Given the ever increasing number of obese patients and obesity related bypass surgery, 
dosing recommendations in the post-bypass population are needed. Using a pop-PK analysis and PK-
PD simulations, we investigated whether adequate moxifloxacin levels are achieved in this 
population.  
Methods: In this modelling and simulation study we used data from a trial on MXF pharmacokinetics.  
In this trial, volunteers who had previously undergone bariatric surgery (at least 6 months prior to 
inclusion), received 2 doses (intravenous and oral) of 400mg MXF administered on 2 occasions. 
Results: In contrast to other papers, we found that MXF pharmacokinetics were best described by a 
3-compartmental model using lean body mass (LBM) as a predictor for MXF clearance. Furthermore, 
we showed that the probability of target attainment (for bacterial eradication) against a hypothetical 
Streptococcus pneumoniaee infection is compromised in patients with higher LBM, especially when 
targeting microorganism with MICs of 0.5 mg/L or higher (PTA approaching zero). When considering 
the targets for suppression of bacterial resistance formation, even at MIC values as low as 0.25 mg/L, 
standard MXF dosing does not attain adequate levels in this population. Furthermore, for patients 
with a LBM of 78 kg or higher, the probability of hitting this target approaches zero.   
Conclusions: Throughout our PK-PD simulation study, it became apparent that, whenever optimal 
bacterial resistance suppression is deemed necessary, the standard MXF dosing will not be sufficient. 
Furthermore, our study emphasises the need for a lean-body mass based individualized dosing of 
MXF in this patient population.    
 
What is already known about this subject 
 Oral bioavailability of moxifloxacin is not altered in post-bariatric surgery patients compared to 
healthy controls. 
 In healthy volunteers a standard 400 mg moxifloxacin dose achieves adequate plasma 
concentrations for the eradication of the infecting micro-organism.  
What this study adds 
 The standard 400 mg moxifloxacin dose is adequate to achieve optimal bacterial eradication in 
infections with a MIC value up to 0.5 mg/L. 
 However, optimal suppression of bacterial resistance formation is not achieved with a standard 
400 mg moxifloxacin dose. 
 Individualization of antimicrobial therapy, using a LBM based dosing regimen, would aid in 
achieving the PK-PD target for optimal suppression of bacterial resistance formation. 
  
Introduction 
Recently, it was suggested that drug PK in post-bariatric surgery patients might differ significantly 
from PK in healthy volunteers due to, among other things, altered drug absorption.[1-3] In a previous 
study on the effect of roux-en-y gastric bypass surgery on moxifloxacin oral bioavailability, our group 
reported that non-compartmental analysis revealed no significant differences in absolute 
bioavailability compared to the absolute bioavailability in healthy volunteers[4]. Although our 
previous analysis showed that, on average, no differences exist between moxifloxacin exposure in 
post-bariatric surgery patients and healthy volunteers, this analysis did not address PK variability 
within the post-bariatric surgery cohort and its potential implications on antimicrobial therapy. 
One of the types of infections where moxifloxacin therapy is deemed necessary are lower 
respiratory tract infections (LRTI), e.g. community acquired pneumoniae (CAP). LRTI’s are the most 
common infectious cause of death in the world and the third most common cause of death 
globally[5]. The pathogens most frequently occurring in CAP[6;7] are Streptococcus pneumoniae and 
to a lesser extent Staphylococcus aureus, both Gram-positive bacteria.   
During antimicrobial chemotherapy there is no straightforward way to monitor the 
pharmacological effect of the treatment. Therefore, based on data from large clinical trials and/or in-
vitro (kinetic) studies, a-priori specific treatment targets are defined in terms of pharmacokinetic-
pharmacodynamic (PK-PD) indices.  
For fluorquinolone antibiotics it is generally accepted that bacterial eradication and clinical 
cure are positively correlated with the AUIC (Eq. 1).  
   (1) 
In the absence of data from large clinical trials on moxifloxacin PK-PD targets for treating LRTI’s, in-
vitro (kinetic) models[8-11] are used to define AUIC targets. For Streptococcus pneumoniae 
infections, Odenholt and Cars[9] advice on the use of an AUIC target of 100 h to guide moxifloxacin 
dosing. This recommendation is in line with earlier findings by Zhanel et al.[12] and Klepser et al.[13]. 
They recommended targeting a free AUIC between 35 h – 63 h[12] and total AUIC between 50 h – 
100 h[13]. 
Besides targets for optimal bacterial eradication, the in-vitro kinetic models provide targets 
for optimal suppression of bacterial resistance formation. In line with the mutant selection window 
hypothesis (MSW) of a.o. Zinner et al.[14] AUIC targets for suppression of bacterial resistance 
formation are usually higher than those for optimal bacterial eradication.  
In this study we will (i) use a population approach to describe pharmacokinetic variability in 
our post-bariatric surgery cohort and (ii) use this model in a PK-PD simulation study to assess the 
target attainment rate in this vulnerable patient population against a hypothetical Streptococcus 
pneumoniae infection.   
Patients and methods 
Model building was based on data from a randomized crossover (oral and intravenous 
administration) trial of moxifloxacin administration to a cohort of post-bariatric surgery patients [4] 
published previously. In short, 12 volunteers, who had undergone roux-en-y gastric bypass at least 6 
months prior to inclusion in the study, were administered moxifloxacin. Each volunteer received two 
single doses of 400 mg moxifloxacin, once as a tablet and once as a 1 hour intravenous infusion, 
separated by a 1 week washout period. The study protocol was approved by the local institutional 
review board of Ghent University Hospital. [4]  
For all patients venous blood samples were taken prior to administration and at serial time points up 
to 72h post-dose. Blood samples were collected in heparinized tubes. After centrifugation, plasma 
was collected and stored at -80°C until analysis. Samples were analysed by a validated HPLC-
Fluorescence assay published earlier.[15] Assay characteristics were evaluated and complied with the 
FDA’s guidance on bio-analytical method validation.[16]  
Pharmacokinetic analysis 
Model building 
The moxifloxacin concentration versus time data, for the oral as well as the intravenous moxifloxacin 
administration, were analysed simultaneously using the FOCE-I estimation algorithm in NONMEM® 
(Version 7.2; GloboMax LLC, Hanover, MD, USA). PLT-Tools (Version 4.6; PLTsoft, San Francisco, CA, 
USA) was used as a graphical user interface to NONMEM®. Furthermore, R®(R foundation for 
statistical computing, Vienna, Austria) was used to graphically assess the model’s goodness-of-fit 
(GOF) and to evaluate the model’s predictive capabilities.  
As a starting point for the development of the structural model we used a 2 compartmental 
model with a linear absorption into and a linear elimination from the central compartment, as 
published earlier by Grosjean and Urien[17] and Simon et al[18]. Subsequently several other higher-
order structural models were fitted to our data and their goodness-of-fit assessed (e.g. LAG-time and 
TRANSIT[19] absorption models). Throughout the course of this iterative procedure of fitting and 
evaluating different models, the Akaike information criterion (AICc) was used to compare the 
goodness-of-fit of different models. In addition, graphical evaluation was used to show the goodness-
of-fit according to the EMA Guideline on Reporting the Results of Population Pharmacokinetic 
Analyses (2007). Furthermore, the condition number was calculated on the covariance matrix of 
parameter estimates to detect possible ill-conditioning. 
Covariate screening was empirically approached by direct incorporation of different 
covariates in the pharmacokinetic model and comparison of the goodness-of-fit using the AICc and 
graphical techniques. Shrinkage (calculated by PLT-Tools) was considered prior to incorporating 
patient covariates in our final structural model. When shrinkage (calculated on the post-hoc 
parameter estimates) was high, inclusion of patient covariates on that particular model parameter 
was deemed unfeasible. Finally, model parsimony was assessed by selectively removing different 
parameters from the model and evaluating the goodness-of-fit of the reduced model. 
               
Internal Model Validation 
R®(R foundation for statistical computing, Vienna, Austria) and PLT-Tools (Version 4.6; PLTsoft, San 
Francisco, CA, USA) were used for model validation. The final pharmacokinetic model was validated 
using different methods: (i) visual predictive check (VPC) method[20] and (ii) the normalized 
prediction distribution error (NPDE) method[21]. Both methods address validation through the use of 
simulated data. Using the final pharmacokinetic population model, with all parameters fixed at final 
parameter estimates, 100 concentrations were simulated for all observed time-points. These 
simulations were performed using the $SIM statement in NONMEM®. Afterwards, for method (i), 
these simulated concentration-time profiles were analysed by non-compartmental pharmacokinetics 
using the PK package (version 1.2-5) for R®. The distribution of the calculated AUC’s for the simulated 
concentration-time profiles were then compared to the observed AUC’s from our dataset (similarly 
calculated using the PK package in R®). The validity of the model is assessed by graphically comparing 
the degree of similarity in the distribution of both sets of calculated AUC’s. For specific details 
regarding method (ii), we refer to the work of Comets et al.[21] 
PK-PD simulations 
Using the calculated AUC24h’s of the simulated concentration-time profiles for the oral data, the AUIC 
was assessed for typical wild-type Streptococcus pneumoniae MIC-values[22]. Subsequently, these 
AUIC’s were plotted against typical AUIC thresholds to visualize the probability of target attainment 
(PTA) against Streptococcus pneumoniae MIC-values for the 400mg dosage regimen.  
Based on the findings by Odenholt and Cars[9] we decided to use an AUIC target for bacterial 
eradication of 100h in our simulation study. Furthermore, based on the results of the in-vitro 
dynamic model published by Zinner et al.[14], on the emergence of resistant Streptococcus 
pneumoniae, we used, as a target for optimal suppression of bacterial resistance formation, a free 
AUIC target of 100 h. When accounting for plasma protein binding (approximately 50% for 
moxifloxacin[23]), this latter free AUIC target is equivalent to an AUIC target of 200 h (to avoid 
confusion with the target for bacterial eradication defined as AUIC rather than free AUIC, in our 
simulation study we will define both targets as (total) AUIC targets). 
Finally, the effect of possible covariates identified in the final pharmacokinetic model, on PK-
PD target attainment, was evaluated using graphical techniques.     
Results 
Patients and Data 
The pharmacokinetic analysis was based on 432 observed total plasma concentrations from 12 
healthy volunteers who recently underwent bariatric surgery, obtained from a study performed by 
De Smet et al.[4] The following patient covariates were available: age, total body weight (TBM), lean 
body mass (LBM) calculated according to James[24], gender, height, serum albumin, creatinine 
clearance estimated using the Cockroft and Gault equation (CrCl) and estimated according to the 
Modification of Diet in Renal Disease equation (MDRD). A summary of the demographic information 
is given in Table 1. The observed concentration-time profiles for all patients are shown in Figure 1.  
Pharmacokinetic Model Building 
According to Grosjean and Urien[17] and Simon et al[18], a two-compartmental model was found 
superior to a one-compartmental model in describing moxifloxacin pharmacokinetics for a standard 
400mg dose. In their final model Grosjean and Urien[17] incorporated an allometric scaling approach 
to predict volume and clearance terms as a function of LBM. On the other hand, Simon et al[18] 
incorporated no parameter-covariate relationship in their population model. Given the thorough 
study conducted by Grosjean and Urien[17] on the body size effects on moxifloxacin 
pharmacokinetics and the number of subjects included in their population analysis relative to Simon 
et al.[18] (number of subjects included in the population analyses respectively 99 and 16) we decided 
to, as a starting point, fit the Grosjean and Urien[17] model with clearance and volume terms 
allometrically scaled to LBM. However, given the relatively small number of subjects in our data set, 
we initially simplified the Grosjean and Urien[17] model by excluding the TRANSIT absorption model 
and treating all model parameters as fixed effects.  
Subsequently, we investigated which of the model parameters were suitable to be included 
in the model as random effects, using the condition number as a measure of ill-conditioning. A 2-
compartmental model treating only the absorption constant (ka), the central volume of distribution 
(Vc) and clearance from the central compartment (CL) as random effects, whilst estimating the 
random effects variance-covariance matrix using a diagonal matrix, provided us with an initial model 
with an acceptable condition number (approximately 10³). The hierarchical model building procedure 
is depicted in Figure 2.  
In their analysis, Grosjean and Urien[17] observe that including a LAG-time or TRANSIT 
compartment model significantly reduces the model’s objective function value. Therefore, after 
addition of an additive error term parameter to our model (which proved to be a requisite to fit an 
absorption model), we fitted both absorption models. Similar to Grosjean and Urien[17], we also 
observed a better fit for both models. However, when our structural model was fitted with an 
additional peripheral compartment we observed an even higher decrease in AICc. (As seen from 
Figure 2) Therefore, as a starting point to append more complex absorption submodels we choose 
the three-compartmental model rather than the two-compartmental model as proposed by Grosjean 
and Urien [17]. 
Subsequently, the TRANSIT compartment and LAG-time absorption model were appended to 
our 3-compartmental model. Both significantly reduced the model’s AICc. However, the condition 
number (approximately 1011 for the LAG-time model) indicated serious ill-conditioning in both cases. 
Although (some of) the estimated parameters for both models would suffer from poor precision, as 
indicated by the condition number, the estimated values (as noted in Figure 2) for the absorption 
model parameters point out that in our dataset little evidence is present to assume a delayed 
absorption of moxifloxacin (estimated LAG-time ≈ 0.19h; estimated mean transit time (MTT) ≈ 
0.19h). Based on the potential problem of poor precision of the estimated parameters and the lack of 
clinical significance of an estimated absorption delay of 0.20 hours , neither the TRANSIT 
compartment nor the LAG-time absorption model were found feasible for inclusion in our structural 
model. 
Finally, we (i) evaluated the feasibility of including covariates other than LBM in our model 
and (ii) studied whether we could simplify our model by removing, among other things, the 
allometric scaling component. After plotting of the post-hoc random effects estimates versus the 
patient covariates and calculation of the shrinkage, we decided to only evaluate CrCl and MDRD for 
incorporation into our model. Hereto, CL was modelled as a linear function of CrCl or MDRD in two 
separate models. The first model, using CrCl as a predictor for CL resulted in a slightly lower AICc 
(∆AICc = -2.3), but goodness-of-fit plots (data not shown) revealed no observable difference in the 
fits of both models. Incorporation of MDRD into the model, as predictor for CL did not result in a 
decrease in AICc, and was therefore not incorporated in our final model.  
By removing or substituting some of the model parameters we studied whether our final 
model could be simplified further.  We started out by fitting a model using an allometric scaling of 
TBM rather than LBM as a way to predict clearance and volume terms. The resulting increase in AICc 
(∆AICc = 27.3) stresses the better model fit using an allometric scaling of LBM rather than TBM as a 
predictor of clearance and volume terms. Furthermore, leaving out the LBM covariate or the 
allometric exponent of 0.75 on the model’s clearance terms did not result in an improved goodness-
of-fit (∆AICc = +56.9 and -0.50 respectively).  
Final PK model & Internal model validation 
The final parameter estimates and the estimated standard errors (SE) for our 3-compartmental 
model are shown in Table 2. Figures 3 and 4 illustrate the model’s goodness-of-fit. In Figure 3 the 
observed plasma concentrations are contrasted with the plasma concentrations predicted by the 
final model, whilst in Figure 4 the observed plasma concentrations are plotted along with the 
median, 5% and 95% percentile of the simulated plasma concentrations for every observed time-
point. As seen from Figure 4, the model gives a good prediction of the mean response at every time-
point. Furthermore, it adequately describes the variation around this mean response (this is seen by 
comparing the observed variation in plasma concentrations at every time-point versus the 
percentiles of the simulated distributions at these time-points.) Alternatively, Figure 5 presents the 
results of the VPC method as described earlier. Again, it is noted that our model provides a good 
estimation of the mean observed AUC, as well as the observed variation around this mean AUC. The 
goodness-of-fit of our model was further confirmed by inspection of the distribution of the NPDE’s 
(Data not shown). Upon comparison against the standard normal distribution, no deviations were 
observed, hence demonstrating the goodness-of-fit of our model.  
PK-PD simulations 
The distribution of simulated AUIC’s for the standard 400 mg daily dose of moxifloxacin against 
typical Streptococcus pneumoniae MIC-values is depicted in Figure 6. To evaluate the expected 
efficacy of this treatment at every MIC-value, we simultaneously plotted the AUIC targets for 
bacterial eradication (AUIC > 100 h) and suppression of bacterial resistance formation (AUIC > 200 h).  
For MIC-values up until 0.5 mg/L, the distribution of simulated AUIC’s remains well above the 
indicated targets for bacterial eradication. However, MIC-values in excess of 0.5 mg/L, the median of 
the predicted AUIC’s is smaller than the proposed target of AUIC >100 h, leading to a PTA (bacterial 
eradication) below 50%. Furthermore, when comparing the simulated AUIC’s versus the proposed 
target[14]  for the control of antimicrobial resistance formation, it stands out that even at MIC values 
as low as 0.25 mg/L the proposed target is attained for only a very small fraction of the simulated 
population (< 25%, given that the 75% percentile of the simulated distribution is below the AUIC 
threshold).     
 To elucidate the effect of LBM on moxifloxacin PK-PD target attainment rate, we simulated 
two patient subpopulations. On one hand we simulated 100 plasma concentration-time profiles for a 
patient population with a LBM of 42 kg (for a person of average height, this would correspond to a 
TBM of around 60 kg, this is the lowest observed LBM in our cohort). On the other hand, simulations 
were performed for a population with a LBM of 78 kg (corresponding to a TBM of approximately 100 
kg, highest observed LBM in our cohort). Figure 7 provides the information on the simulated AUIC’s 
as a function of Streptococcus pneumoniae MIC-values. From this graph it is apparent that, for 
patients with a higher LBM, the PTA at every MIC-value is lower as compared to patients with a lower 
LBM (on average, the AUC24h in the high LBM group is  40.5 % lower than the AUC24h in the low LBM 
group).  
Furthermore, , all simulated AUIC’s from the high LBM group drop below the recommended 
AUIC target of 100 h when targeting a microorganism with an MIC of 0.5mg/L, and hence the PTA for 
bacterial eradication for those patients approaches zero. Furthermore, when evaluating the PTA for 
suppression of bacterial resistance formation, for patients with a higher LBM, this PTA approaches 
zero at MIC values as low as 0.25 mg/L.        
Discussion 
Many authors reported in literature that moxifloxacin pharmacokinetics were best described using a 
1-compartmental [25] or a two-compartmental [17;18] model, with[17;25] or without[18] additional 
parameters to account for the observed absorption delay. In contrast to these observations, we 
found that a three-compartmental model produces a superior fit as compared to a two-
compartmental model. This discrepancy is explained by the difference in sampling times between our 
study (up until 72 hours post-dose) and the studies reported in literature earlier (restricted to 24 
hours post-dose). Given the relatively short sampling schemes of the foregoing studies, it would have 
been nearly impossible for these authors to reliably identify this third compartment. Although this 
third compartment might not have a significant impact on the single dose simulations performed in 
our study, it is expected to have an impact whenever trying to simulate moxifloxacin exposure after 
repeated doses. Moreover, not taking into account this 3rd compartment when simulating 
moxifloxacin PK will result in an underestimation of a subjects true (unobservable) AUC.     
As opposed to Florian et al. [25] and Grosjean and Urien [17] our study, as well as the study 
reported by Simon et al. [18], found no evidence in favour of a (clinically significant) delayed 
absorption and therefore no LAG-time nor TRANSIT-model was fitted. These differences are likely 
explained by the fact that Florian et al. [25] and Grosjean and Urien [17] used data originating from 
double-blinded trials in which moxifloxacin tablets were overencapsulated, thereby most likely 
prolonging the absorption phase. 
Based on our data, it seems that allometric scaling of LBM by an exponent of 0.75 is superior, 
compared to a simple linear regression model, for the prediction of moxifloxacin clearance terms. 
Furthermore, in concordance with the findings of Grosjean and Urien [17] we found that LBM rather 
than TBM should be used in the prediction of moxifloxacin pharmacokinetics. However, since it is 
well known[26] that the James[24] equation tends to overestimate the subjects’ percentage body fat, 
thereby underestimating the true LBM, care has to be taken when using this model to estimate PK 
parameters in the morbidly obese (BMI > 30 kg/m²).    
Although the appropriate PK-PD targets to pursue when trying to optimise moxifloxacin 
treatment are still under debate , our PK-PD simulations show that, when taking into account 
currently propagated AUIC thresholds, in this population the PTA for bacterial eradication against a 
Streptococcus pneumoniae organism with a MIC-value of 0.5 mg/L is already below 50%. When we 
look at the PTA for the simulated population with LBM of 78 kg, this probability approaches zero at 
the MIC value of 0.5 mg/L. Furthermore, when evaluating the PTA of suppression of bacterial 
resistance formation it is apparent that at standard 400mg doses of moxifloxacin, even at MIC values 
of 0.25 mg/L this PTA is unacceptably low.  
 Given the relatively low prevalence of MIC-values of 0.50 mg/L for the wild type 
Streptococcus pneumoniae species[22], at first glance, our results do not seem to have an important 
impact on the average PTA for bacterial eradication of moxifloxacin therapy in this population. 
However, as indicated in Figure 7, for subjects with a LBM of 78 kg, approximately 25 % will attain 
AUIC values below the recommended target of 100 h. (as seen by the near-overlap of the 25 % 
percentile of the simulated distribution and the dashed line for the AUIC target of 100 h) Moreover, 
although not included in our simulated population, from our model it is apparent that post-bariatric 
surgery patients with a LBM higher than 78 kg are likely to fail in achieving an AUIC of 100 h. 
When considering an AUIC target of 200 h, as proposed in literature[14] to optimally supress 
bacterial resistance formation, we see that the overall PTA is low (well below 50 %) even at MIC 
values of 0.25 mg/L for the entire simulated population. Furthermore, when considering the effect of 
LBM on this particular PTA, we observe that for subjects with a higher LBM (78 kg) the PTA for 
suppression of bacterial resistance formation approaches zero at this MIC value.   
This study has a number of limitations. At first, changes induced in the PK of moxifloxacin by 
the infection are not captured. Furthermore, given that the subjects in our study were included after 
having stabilised from their bariatric surgery, i.e. they were in a generally good condition, the 
observed PK variability might underestimate the variability seen in infected patient populations. The 
consequence of this limitation is that both PK and the probability of target attainment are likely to be 
even more variable in a patient population treated with moxifloxacin.  
 Conclusions 
This analysis demonstrates that for antimicrobial dosing the “one dose fits all” paradigm is not 
correct. Throughout this simulation study, it was clear that optimization of moxifloxacin dosing 
should take into account the effect LBM on PK and, ultimately, the PK-PD endpoints. Our study 
results show that in order to optimize moxifloxacin chemotherapy, both in terms of bacterial 
eradication and optimal suppression of resistance development during therapy, individualized dosing 
strategies should be developed.
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 Tables 
 
TABLE 1 
Table 1 Summary of patient demographics.   
Characteristic median [range] 
Age (years) 41 [25 – 57] 
TBM (kg) 78.1 [57.4 – 104.0] 
LBM (kg) 51.7 [41.9 – 77.6] 
Height (m) 1.68 [1.58 – 1.99] 
Sex (# males / # females) 4 / 8 
Serum albumin (g/dL) 3.96 [3.54 – 4.40] 
CrClCockroft-Gault (mL/min) 131.9 [100.4 – 221.5] 
CrClMDRD (mL/min) 101.5 [91.9 – 134.9] 
 
TABLE 2 
Table 2 Population parameter estimates of the final pharmacokinetic model and the associated 95% bootstrap 
confidence intervals calculated on 100 bootstrap samples. All model parameters except ka were centered for a typical 
subject with a LBM of 60 kg. 
Parameter Final pharmacokinetic model 
Fixed effects  
ka (h
-1) 0.95 [0.72 – 1.21] 
 (L) 47.7 [31.6 – 78.6] 
 (L/h) 8.60 [7.80 – 9.70] 
 (L) 61.5 [37.6 – 75.7] 
 (L/h) 105.3 [55.2 – 140.0] 
 (L) 48.4 [34.4 – 92.9] 
 (L/h) 1.35 [1.23 – 1.56] 
 
Inter-individual variability 
 
ω2 (ka) 0.24 
ω2 (V1) 0.14 
ω2 (Cl) 0.04 
 
Residual error 
 
σ2 (Proportional) 0.03 
ka: absorption constant; V1: Volume of distribution for the central compartment; Cl: Clearance from 
central compartment; V2 & V3: Volume of distribution for the first and second peripheral 
compartment; Q2 & Q3: Inter-compartmental clearance from the central compartment to the first 
and second peripheral compartment; ω2: Variance terms describing inter-individual variation in a 
particular model parameter; σ2: Variance term describing residual unexplained error 
 Legends to figures 
 
Figure 1 Observed moxifloxacin plasma-concentration time profiles after oral dosing (left graph) and after a 1 hour i.v. 
infusion (right graph)  The LLOQ of the assay is depicted by the dashed line. 
Figure 2 Overview of the structural model building: Vc: Volume of distribution for the central compartment; CL: Clearance 
from central compartment; Vp & Vp2: Volume of distribution for the first and second peripheral compartment; Qp & Qp2: 
Inter-compartmental clearance from the central compartment to the first and second peripheral compartment; θLag: 
Absorption lag time; θMTT: Mean transit time; θN: Number of transit compartments; σAdd: Residual error variance 
explained by the additive error term.  
Figure 3 Goodness-of-fit plots for our final PK model, insets show the first 3 hours post dosing. The black line represents a 
LOESS smoother. 
Figure 4 Observed moxifloxacin plasma concentrations after a standard 400 mg oral dose (open circles). The model 
simulated median moxifloxacin plasma concentration (solid line) along with the 5% and 95% percentile (dashed lines) 
from the simulations are shown to assess the model’s goodness-of-fit.    
Figure 5 Visual predictive check comparing the distribution of the 100 model simulated AUC72 values (histogram on top) 
against the observed AUC72 values (open circles) after a standard 400 mg oral dose of moxifloxacin.    
Figure 6 AUIC values calculated as the ratio of the model simulated moxifloxacin AUC24 values after a standard 400mg 
oral dose versus the theoretical Streptococcus pneumoniae MIC-values. Simultaneously the AUIC cut-off values for 
bacterial eradication as well as suppression of bacterial resistance formation, as proposed in literature, are shown. (long 
dashes: AUIC = 100; short dashed lines: AUIC = 200) 
Figure 7 AUIC values calculated as the ratio of the model simulated moxifloxacin AUC24 values for subjects with a LBM of 
42 kg (open squares) and 78 kg (solid squares) after a standard 400mg oral dose versus the theoretical Streptococcus 
pneumoniae MIC-values. Simultaneously the AUIC cut-off values for bacterial eradication as well as suppression of 
bacterial resistance formation, as proposed in literature, are shown. (long dashes: AUIC = 100; short dashed lines: AUIC = 
200) Overall, AUIC values for the high LBM group are 40.5 % lower than those for the low LBM group. 
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•
Figure 1 Observed moxifloxacin plasma-concentration time profiles after oral dosing (left graph) and after a 1 hour i.v. infusion (right graph)  The LLOQ of the 
assay is depicted by the dashed line. 
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FIGURE•2•
 
 
Vc: Volume of distribution for the central compartment; CL: Clearance from central compartment; Vp 
& Vp2: Volume of distribution for the first and second peripheral compartment; Qp & Qp2: Inter-
compartmental clearance from the central compartment to the first and second peripheral 
compartment; •Lag: Absorption lag time; •MTT: Mean transit time; •N: Number of transit 
compartments; Add: Residual error variance explained by the additive erro  term.  
 
FIGURE•3•
Figure 3 Goodness-of-fit plots for our final PK model, insets show the first 3 hours post dosing. The black line represents a LOESS smoother. 
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FIGURE•4•
 
Figure 4 Observed moxifloxacin plasma concentrations after a standard 400 mg oral dose (open circles). The model 
simulated median moxifloxacin plasma concentration (solid line) along with the 5% and 95% percentile (dashed lines) 
from the simulations are shown to assess the model’s goodness-of-fit.    
 
 
FIGURE•5•
 
Figure 5 Visual predictive check comparing the distribution of the 100 model simulated AUC72 values (histogram on top) 
against the observed AUC72 values (open circles) after a standard 400 mg oral dose of moxifloxacin.   
 
 
FIGURE•6•
 
Figure 6 AUIC values calculated as the ratio of the model simulated moxifloxacin AUC24 values after a standard 400mg 
oral dose versus the theoretical Streptococcus pneumonia MIC-values. Simultaneously the AUIC cut-off values for 
bacterial eradication as well as suppression of bacterial resistance formation, as proposed in literature, are shown. (long 
dashes: AUIC = 100; short dashed lines: AUIC = 200) 
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Figure 7 AUIC values calculated as the ratio of the model simulated moxifloxacin AUC24 values for subjects with a LBM of 
42 kg (open squares) and 78 kg (solid squares) after a standard 400mg oral dose versus the theoretical Streptococcus 
pneumonia MIC-values. Simultaneously the AUIC cut-off values for bacterial eradication as well as suppression of 
bacterial resistance formation, as proposed in literature, are shown. (long dashes: AUIC = 100; short dashed lines: AUIC = 
200) Overall, AUIC values for the high LBM group are 40.5 % lower than those for the low LBM group. 
 
 
 
 
 
